Search Results - "Walls, Marlena"

Identification of sphingolipid metabolites that induce obesity via misregulation of appetite, caloric intake and fat storage in Drosophila by Walls, Jr, Stanley M, Attle, Steve J, Brulte, Gregory B, Walls, Marlena L, Finley, Kim D, Chatfield, Dale A, Herr, Deron R, Harris, Greg L

“…Obesity is defined by excessive lipid accumulation. However, the active mechanistic roles that lipids play in its progression are not understood. Accumulation…”
Get full text

Lipid Nanoparticle-Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth by Huang, Xinqiang, Magnus, Jill, Kaimal, Vivek, Karmali, Priya, Li, Jian, Walls, Marlena, Prudente, Rene, Sung, Eric, Sorourian, Mehran, Lee, Robin, Davis, Scott, Yang, Xia, Estrella, Heather, Lee, Edmund C, Chau, B Nelson, Pavlicek, Adam, Zabludoff, Sonya

“…Hepatocellular carcinoma (HCC) is one of the most common human malignancies with poor prognosis and urgent unmet medical need. Aberrant expression of multiple…”
Get full text

Targeting the mTOR pathway in tumor malignancy by Cheng, Hengmiao, Walls, Marlena, Baxi, Sangita M, Yin, Min-Jean

“…The mammalian target of rapamycin (mTOR) plays a critical role in the regulation of cell growth, proliferation,and metabolism by integrating growth factor…”
Get more information

Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design by Wei, Ping, Walls, Marlena, Qiu, Ming, Ding, Richard, Denlinger, Robert H, Wong, Anthony, Tsaparikos, Kosta, Jani, Jitesh P, Hosea, Natilie, Sands, Michelle, Randolph, Sophia, Smeal, Tod

“…Aberrant regulation of Notch signaling has been implicated in tumorigenesis. Proteolytic release of the Notch intracellular domain (NICD) by gamma-secretase…”
Get full text

Abstract 356: Novel conditionally active biologic (CAB) antibody targeting EpCAM demonstrates anti-tumor efficacy in vivo by Chang, Cathy, Frey, Gerhard, Sharp, Leslie, Boyle, William (Bill) J., Wang, Jing, Xing, Charles, Liu, Haizhen, Wheeler, Christina, Walls, Marlena, Short, Jay M.

“…Abstract Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating Ca2+-independent homotypic cell-cell adhesion during cell…”
Get full text

Abstract 2708: Potent CAB CTLA4 antibody to reduce immune side effects and toxicities associated with single-agent and combination cancer immuno therapies by Sharp, Leslie, Chang, Cathy, Frey, Gerhard, Liu, Haizhen, Xing, Charles, Wang, Jing, Walls, Marlena, Wheeler, Christina, Ben, Yong, Boyle, William J., Short, Jay M.

“…Abstract CTLA4 is a receptor on T cells that acts as a brake on their activation during immune responses, and when blocked can stimulate cancer…”
Get full text

Discovery of 1‑{(3R,4R)‑3-[({5-Chloro-2-[(1-methyl‑1H‑pyrazol-4-yl)amino]‑7H‑pyrrolo[2,3‑d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants by Cheng, Hengmiao, Nair, Sajiv K, Murray, Brion W, Almaden, Chau, Bailey, Simon, Baxi, Sangita, Behenna, Doug, Cho-Schultz, Sujin, Dalvie, Deepak, Dinh, Dac M, Edwards, Martin P, Feng, Jun Li, Ferre, Rose Ann, Gajiwala, Ketan S, Hemkens, Michelle D, Jackson-Fisher, Amy, Jalaie, Mehran, Johnson, Ted O, Kania, Robert S, Kephart, Susan, Lafontaine, Jennifer, Lunney, Beth, Liu, Kevin K.-C, Liu, Zhengyu, Matthews, Jean, Nagata, Asako, Niessen, Sherry, Ornelas, Martha A, Orr, Suvi T. M, Pairish, Mason, Planken, Simon, Ren, Shijian, Richter, Daniel, Ryan, Kevin, Sach, Neal, Shen, Hong, Smeal, Tod, Solowiej, Jim, Sutton, Scott, Tran, Khanh, Tseng, Elaine, Vernier, William, Walls, Marlena, Wang, Shuiwang, Weinrich, Scott L, Xin, Shuibo, Xu, Haiwei, Yin, Min-Jean, Zientek, Michael, Zhou, Ru, Kath, John C

“…First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately,…”
Get full text

Abstract 833: Anti-tumor efficacy of BA3021, a novel Conditionally Active Biologic (CAB) anti-ROR2 ADC by Sharp, Leslie L., Chang, Cathy, Frey, Gerhard, Wang, Jing, Liu, Haizhen, Xing, Charles, Yalcin, Safak, Walls, Marlena, Ben, Yong, Boyle, William J., Short, Jay M.

“…Abstract ROR2 is a developmentally regulated member of the receptor tyrosine kinase orphan receptor (ROR) family and is a non-canonical receptor for selected…”
Get full text

Abstract 827: Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC by Sharp, Leslie L., Chang, Cathy, Frey, Gerhard, Wang, Jing, Liu, Haizhen, Xing, Charles, Yalcin, Safak, Walls, Marlena, Ben, Yong, Boyle, William J., Short, Jay M.

“…Abstract AXL is a TAM family receptor tyrosine kinase that has been implicated in the pathogenesis of many cancer types. The high level of expression on the…”
Get full text

Retraction notice to “A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells” by Mehta, Pramod P., Kung, Pei-Pei, Yamazaki, Shinji, Walls, Marlena, Shen, Andrea, Nguyen, Leslie, Gehring, Michael R., Los, Gerrit, Smeal, Tod, Yin, Min-Jean

Get full text

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216 by WALLS, Marlena, BAXI, Sangita M, YIN, Min-Jean, MEHTA, Pramod P, LIU, Kevin K.-C, JINJIANG ZHU, ESTRELLA, Heather, CHUNZE LI, ZIENTEK, Michael, QING ZONG, SMEAL, Tod

“…Constitutive activation of phosphoinositide 3-kinase (PI3K) occurs frequently in many human tumors via either gene mutation in the p110α catalytic subunit of…”
Get full text

Abstract 4467: Targeting both PI3K/mTOR and EGFR pathways leads to synergistic anti-tumor activity in erlotinib resistant non-small-cell lung cancers by Mehta, Pramod P., Baxi, Sangita M., Walls, Marlena, Chen, Stella, Cheng, Hengmiao, Li, Gang, Smeal, Tod, Yin, Min-Jean

“…Abstract NSCLCs with EGFR mutations, such as a deletion in exon 19 (del E746-A750) or point mutation in exon 21 (L858R), are sensitive to TKI (gefitinib and…”
Get full text

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design by Cheng, Hengmiao, Li, Chunze, Bailey, Simon, Baxi, Sangita M, Goulet, Lance, Guo, Lisa, Hoffman, Jacqui, Jiang, Ying, Johnson, Theodore Otto, Johnson, Ted W, Knighton, Daniel R, Li, John, Liu, Kevin K.-C, Liu, Zhengyu, Marx, Matthew A, Walls, Marlena, Wells, Peter A, Yin, Min-Jean, Zhu, Jinjiang, Zientek, Michael

“…PI3K, AKT, and mTOR are key kinases from PI3K signaling pathway being extensively pursued to treat a variety of cancers in oncology. To search for a…”
Get full text

Identification of Sphingolipid Metabolites That Induce Obesity via Misregulation of Appetite, Caloric Intake and Fat Storage in Drosophila: e1003970 by Jr, Stanley MWalls, Attle, Steve J, Brulte, Gregory B, Walls, Marlena L, Finley, Kim D, Chatfield, Dale A, Herr, Deron R, Harris, Greg L

“…Obesity is defined by excessive lipid accumulation. However, the active mechanistic roles that lipids play in its progression are not understood. Accumulation…”
Get full text

Abstract 2594: Characterization of a novel irreversible third generation EGFR TKI that targets T790M-mediated resistant EGFR-mutant NSCLC while sparing wild type EGFR by Zientek, Mike, Baxi, Sangita, Cheng, Henry, Fantin, Valeria, Feng, Jun Li, Given, Allison, Goldberg, Zelanna, Guo, Jie, Hemkens, Michelle, Kath, John, Lafontaine, Jennifer, Li, Gary, Mehta, Pramod, Murray, Brion, Nair, Sajiv, Planken, Simon, Ray, Chad, Wang, Yuli, Shi, Manli, Sistla, Anand, Smeal, Tod, Stevens, Greg, Tan, Wei, Vicini, Paolo, Walls, Marlena, Yang, Liu, Yin, Min-Jean, Weinrich, Scott L.

“…Abstract Activating mutations in EGFR confer constitutive activity providing the oncogenic drive in EGFR-mutant NSCLC. First and 2nd generation EGFR tyrosine…”
Get full text

Abstract 3257: Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor, PF-4989216 by Walls, Marlena, Baxi, Sangita M., Mehta, Pramod P., Epps, Elizabeth, Estrella, Heather, Liu, Kevin KC, Zhu, JinJiang, Li, Chunze, Smeal, Tod, Yin, Min-Jean

“…Abstract Aberrant PI3K/AKT signaling occurs commonly in cancer. Gene mutation, amplification, and copy number gains in the catalytic p110α of PI3K have been…”
Get full text

Abstract 3578: A novel and selective 3-phosphoinositide-dependent kinase-1 inhibitor, PF-5177624, blocks insulin-like growth factor-1 induced tumorigenesis in breast cancer cells by Baxi, Sangita M., Walls, Marlena, Murphy, Sean, Ermolieff, Jacques, Smeal, Tod, Yin, Min-Jean

“…Abstract Phosphatidylinositol 3-kinases (PI3Ks) phosphorylate membrane phosphatidylinositides to generate phosphatidylinositol 3,4,5-triphosphate (PIP3); PIP3…”
Get full text

A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells by Mehta, Pramod P, Kung, Pei-Pei, Yamazaki, Shinji, Walls, Marlena, Shen, Andrea, Nguyen, Leslie, Gehring, Michael R, Los, Gerrit, Smeal, Tod, Yin, Min-Jean

“…Hsp90 is required for conformational maturation and stability of numerous key signaling proteins (clients) involved in cell proliferation and transformation…”
Get full text

Abstract A50: Targeting 3-phosphoinositide-dependent kinase-1 and mammalian target of rapamycin synergistically inhibits cell proliferation of breast cancer cells by Walls, Marlena, Baxi, Sangita M., Murphy, Sean, Johnson, Teddy W., Tod, Smeal, Yin, Min-Jean

“…Abstract Aberration of receptor tyrosine kinases (RTKs), PTEN (phosphatase and tensin homolog deleted on chromosome 10), and PIK3CA (encodes the p110 subunit…”
Get full text

Abstract 4479: Targeting non-small cell lung cancer cells harboring a PIK3CA mutation by a novel and oral PI3K selective inhibitor, PF-4989216 by Walls, Marlena, Mehta, Pramod P., Baxi, Sangita M., Liu, Kevin, Li, Chunze, Smeal, Tod, Yin, Min-Jean

“…Abstract Aberrant phosphatidylinositol 3-kinase (PI3K)/AKT signaling occurs commonly in cancer. Gene mutation, amplification, and copy number gains of the PI3K…”
Get full text